Sanofi-Aventis Goes Hostile With Genzyme Bid
Wall Street Journal
PARIS (Dow Jones)–French pharmaceutical giant Sanofi-Aventis SA (SNY) Monday sought to move forward with its attempt to buy Genzyme Corporation (GENZ) by going hostile and taking its $18.5 billion or $69 per
Genzyme advises shareholders not to act on bid MarketWatch

Health giant Sanofi-Aventis launches bid for Genzyme AFP
Sanofi-Aventis Versus Genzyme As Sanofi-Aventis Initiates Hostile Offer All About Top News
Reuters -AHN | All Headline News -Xconomy
all 768 news articles »



Post a Comment
* Your Name:

* Your Email:

(NEVER publicly displayed)
Website URL:
* Security Image:
Security Image Generate New
Copy the numbers and letters from the security image:
* Your Comment:
No HTML tags are permitted in comments.
By submitting, you agree with our Publishing Policy. Please note that we may publish your comment in other sections of this site.